Search Within

Population Sciences Research Program

  1. "Matthew Matasar"
  2. "Solid Tumor Oncology Division"
  3. "Breast Medicine Service"
  4. "Epidemiology and Biostatistics"
  5. "Steven Horwitz"
Formats
  1. Meeting Abstract (14)
  2. Journal Article (4)
Groups
  1. Breast Medicine Service (18)
  2. Center for Hematologic Malignancies (18)
  3. Department of Medicine (18)
  4. Epidemiology and Biostatistics (18)
  5. Hematologic Malignancies, Division of (18)
  6. Lymphoma (18)

More Groups

People
  1. Andrew Zelenetz (18)
  2. David Straus (18)
  3. Matthew Matasar (18)
  4. Steven Horwitz (18)
  5. Pamela Drullinsky (17)
  6. Alison Moskowitz (16)

More People

Years
  1. 2022 (1)
  2. 2021 (2)
  3. 2020 (1)
  4. 2019 (2)
  5. 2017 (8)
  6. 2016 (3)

More Years

Publications
  1. Blood (9)
  2. Hematological Oncology (3)
  3. Journal of Clinical Oncology (3)
  4. Clinical Cancer Research (2)
  5. Clinical Lymphoma, Myeloma and Leukemia (1)
Publishers
  1. American Society of Hematology (9)
  2. American Society of Clinical Oncology (3)
  3. Wiley Blackwell (3)
  4. American Association for Cancer Research (2)
  5. Elsevier Inc. (1)

Results (18)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring
    Journal Article

    Stewart, C. M.; Michaud, L.; Whiting, K.; Nakajima, R.; Nichols, C.; De Frank, S.; Hamlin, P. A. Jr; Matasar, M. J.; Gerecitano, J. F.; Drullinsky, P.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Update of a phase II, multicenter study of high-dose chemotherapy with autologous stem cell transplant followed by maintenance romidepsin for T-cell lymphoma
    Meeting Abstract

    Khan, N.; Khimani, F.; Shustov, A. R.; Shadman, M.; Ruan, J.; Moskowitz, A. J.; Straus, D. J.; Kumar, A.; Sauter, C. S.; Zelenetz, A. D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S. V.; Drill, E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Interim analysis from a prospective multicenter study of next-generation sequencing minimal residual disease assessment and CT monitoring for surveillance after frontline treatment in diffuse large B-cell lymphoma
    Meeting Abstract

    Kumar, A.; Westin, J.; Schuster, S. J.; Nowakowski, G. S.; Lossos, I. S.; Batlevi, C. L.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin combined with AVD chemotherapy and radiotherapy in patients with newly diagnosed early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L. E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S.; Drill, E.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase II, multicenter study of high dose chemotherapy with autologous stem cell transplant followed by maintenance therapy with romidepsin for T-cell lymphoma
    Meeting Abstract

    Khan, N.; Shustov, A. R.; Khimani, F.; Shadman, M.; Cassaday, R. D.; Ruan, J.; Moskowitz, A. J.; Zelenetz, A. D.; Noy, A.; Straus, D. J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Phase I dose escalation of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL)
    Meeting Abstract

    Batlevi, C. L.; Hamlin, P. A.; Matasar, M. J.; Horwitz, S. M.; Gerecitano, J. F.; Moskowitz, C. H.; Straus, D. J.; Zelenetz, A. D.; Drullinsky, P.; Copeland, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Chen, R. W.; Constine, L. S.; Courtien, A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Impact of PET staging of follicular lymphoma on treatment outcomes and prognosis
    Meeting Abstract

    Alperovich, A.; Batlevi, C. L.; Intlekofer, A. M.; Moskowitz, C. H.; Horwitz, S. M.; Zelenetz, A. D.; Palomba, M. L.; Moskowitz, A. J.; Gerecitano, J.; Hamlin, P. A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Defining progression free survival after multiple lines of therapy and impact of dynamic changes in FLIPI for multiply relapsed follicular lymphoma in the rituximab era treated at Memorial Sloan Kettering Cancer Center (MSKCC)
    Meeting Abstract

    Alperovich, A.; Batlevi, C.; Smith, K.; Ying, Z.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P.; Horwitz, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2017)

    Fulltext@MSK | Save